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Cannabis Control Commission Orders Quarantine on All Marijuana Vaping
Products Except Medical Use Flower Vaporizers
BOSTON—Following a Superior Court ruling and investigative  ndings from
the US Centers for Diseases Control and Prevention (CDC), the Cannabis
Cannabis Control
Commission Orders
Quarantine on All Marijuana
Vaping Products Except
Medical Use Flower
Vaporizers
COMMONWEALTH OF MASSACHUSETTS
Control Commission (Commission) on Tuesday issued a quarantine order for
marijuana products and devices that rely on vaporization or aerosolization,
including, but not limited to, vape pens, vape cartridges, aerosol products,
and inhalers, in order to protect the public health, safety, and welfare of the
citizens of Massachusetts. The Commission’s quarantine order does not
apply to medical-use marijuana vaping devices designed exclusively for
marijuana  ower.
As part of an ongoing investigation into a nationwide outbreak of e-cigarette,
or vaping product use-associated lung injuries, on Friday, November 8, the
CDC reported “direct evidence of vitamin E acetate at the primary site of
injury within the lungs.” Their announcement came three days after
Massachusetts Superior Court Judge Douglas Wilkins ruled the Commission
is the single state entity authorized to regulate marijuana.
On Thursday, November 7, the Commission voted unanimously to begin a
process of developing regulations relative to medical and adult use of
marijuana vaping products and rea rmed the Executive Director’s authority
to take administrative action to protect the public health, safety, or welfare.
Additionally, the Commission is formally requesting that the Department of
Public Health (DPH) provide the Commission with all information it has
collected regarding cases of pulmonary illness reported from September 24
to November 7, 2019. The Commission will continue to coordinate with DPH
to monitor and evaluate causes and  ndings related to associated lung
injuries in Massachusetts.
The Commission’s existing testing regulations and protocols do not require
testing for vitamin E acetate. Based on current manufacturing processes, it is
possible that legal marijuana products sold in the state could contain vitamin
E acetate or other potential ingredients of concern. As part of the
Commission’s quarantine order issued Tuesday, licensed Marijuana
Establishments and Medical Marijuana Treatment Centers are required to
quarantine products on administrative hold in the state’s mandated seed-to-
sale tracking system of record.
The Commission is communicating with Independent Testing Laboratories to
understand their capability of testing for ingredients such as vitamin E
acetate. Currently, the Commission’s regulations require all marijuana
products to undergo contaminant testing, including testing for heavy metals,
by an Independent Testing Laboratory accredited to the International
Organization for Standardization 17025 (ISO/IEC 17025: 2017) and in
accordance with the Commission’s Protocol for Sampling and Analysis of
Finished Medical Marijuana Products and Marijuana-infused Products.
In September, following the Governor’s declaration of a vaping public health
emergency, the Commission issued memoranda to licensees, patients, and
clinicians and circulated a voluntary, anonymous survey to licensees to
understand the ingredients and sources of additives used in marijuana
products manufactured in Massachusetts. The Commission is analyzing the
response data as part of an initial investigation. As part of its 2019 regulatory
process, the Commission also strengthened existing labeling requirements in
order for patients and consumers to have more information about the
ingredients used in items such as marijuana concentrates and extracts
including the additives infused or incorporated during the manufacturing
process such as speci c thickening agents, thinning agents, and terpenes.
The Commission’s forthcoming regulatory process regarding adult and
medical use of marijuana vaporization products will be open to public
comment and focus on the requirements for extracts, concentrates, and any
accessories or devices used for vaporizing marijuana. In their vote Thursday,
the Commission agreed to set standards for ingredients, labeling, testing,
sourcing, storage of marijuana products intended for vaporization, the
manufacturing and consumption processes of marijuana products and
marijuana accessories, and more. More information about the regulatory
process will be announced later.
For more information about the quarantine order, visit
MassCannabisControl.com, contact the Commission at 617-701-8400 or
CannabisCommission@mass.gov, or follow the Commission on Facebook
and Twitter.
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